7,701 candidates vie for entry in fractured oncology market

Market research in oncology suggests Swiss pharma giant Roche (ROG: SIX) is likely to remain dominant in this therapy area for the foreseeable future, in an increasingly diverse and competitive landscape.

The report from analysts  GBI Research, which looks at pipeline developments in this area, finds that none of the likely new drugs up to 2023 can be expected to be top current blockbusters such as Revlimid (lenalidomide), Opdivo (nivolumab) and Avastin (bevacizumab).

The researchers say that entrenched products now compete for market share even in the second-line segment of most indications, meaning that new products require longer to carve out a slice of the market.